Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

June 2018 | 223 pages | ID: R567B31FB28EN
La Merie Publishing

Abstracts

Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. The six reports of this package are covering immunotherapeutics against six important intracellular cancer targets:

• Melanoma-associated antigen A: MAGE-A
• New York esophageal squamous cell carcinoma-1: NY-ESO-1
• Human telomerase reverse transcriptase: hTERT
• Wilms‘ tumor 1: WT1
• Preferentially expressed antigen in melanoma: PRAME
• Survivin

This report package includes six Competitor Analysis reports covering immunotherapeutics directed to six different important cancer targets. The original reports were published in May and June 2018, respectively:

• Competitor Analysis: MAGE-A-Targeted Immunotherapy
• Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
• Competitor Analysis: hTERT-Targeted Immunotherapy
• Competitor Analysis: WT1-Targeted Immunotherapy
• Competitor Analysis: PRAME-Targeted Immunotherapy
• Competitor Analysis: Survivin-Targeted Immunotherapy

Detailed report descriptions and tables of contents from the reports can be found on the respective product page. The reports can be acquired separately or as a package with a 40% discount on list prices.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

COMPETITOR ANALYSIS: MAGE-A-TARGETED IMMUNOTHERAPY

1) MAGE-A-TARGETED IMMUNOTHERAPY:
  MAGE-A1
  MAGE-A3
  MAGE-A4
  MAGE-A6
  MAGE-A10
  MAGE-A12
2) Corporate & Institutional MAGE-A Immunotherapy R&D Pipelines

COMPETITOR ANALYSIS: NY-ESO-1-TARGETED IMMUNOTHERAPY

1) NY-ESO-1-TARGETED IMMUNOTHERAPY
  NY-ESO-1 Selective Cancer Vaccines
  NY-ESO-1 Specific, Multi-Target Cancer Vaccines
  NY-ESO-1 Selective Adoptive Cell Therapy
  NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
  NY-ESO-1 Selective Recombinant Antibodies & Proteins
2) Corporate & Institutional NY-ESO-1 Immunotherapy R&D Pipelines

COMPETITOR ANALYSIS: HTERT-TARGETED IMMUNOTHERAPY

1) HTERT-TARGETED IMMUNOTHERAPY
  hTERT-Selective Cancer Vaccines
  hTERT-Specific, Multi-Target Cancer Vaccines
  hTERT-Targeted Adoptive Cell Therapy
  Other hTERT-Targeted Immunotherapies
2) Corporate & Institutional hTERT Immunotherapy R&D Pipelines

COMPETITOR ANALYSIS: WT1-TARGETED IMMUNOTHERAPY

1) WT1-TARGETED IMMUNOTHERAPY
  Selective WT1-Targeted Vaccines
  WT1-Specific, Multi-Target Vaccines
  WT1-Selective Adoptive Cell Therapy
  WT1-Specific, Multi-Target Adoptive Cell Therapy
  WT1-Targeted Antibodies
2) Corporate & Institutional WT1 Immunotherapy R&D Pipelines

COMPETITOR ANALYSIS: PRAME-TARGETED IMMUNOTHERAPY

1)PRAME-TARGETED IMMUNOTHERAPY
  PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
  PRAME-Selective Cellular & Recombinant Immunotherapies
  PRAME-Specific, Multi-Target Adoptive Cell Therapy
2) Corporate & Insitutional PRAME Immunotherapy R&D Pipelines

COMPETITOR ANALYSIS: SURVIVIN-TARGETED IMMUNOTHERAPY

1) SURVIVIN-TARGETED IMMUNOTHERAPY
  Survivin-Selective Cancer Vaccines
  Survivin-Specific, Multi-Antigen Cancer Vaccines
  Survivin-Selective Adoptive T-Cell Therapy & Oncolytic Viral Immunotherapy
  Survivin-Specific, Multi-Target Adoptive T-Cell Therapy
2) Corporate Survivin Immunotherapy R&D Pipelines